Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study

Gonzalez-Porras, Jose Ramon; Belhassen-Garcia, Moncef; Lopez-Bernus, Amparo; Vaquero-Roncero, Luis Mario; Rodriguez, Beatriz; Carbonell, Cristina; Azibeiro, Raul; Hernandez-Sanchez, Alberto; Martin-Gonzalez, Jose Ignacio; Manrique, Juan Miguel; Alonso-Claudio, Gloria; Alvarez-Navia, Felipe; Madruga-Martin, Jose Ignacio; Macias-Casanova, Ronald Paul; García-Criado, Jorge; Lozano, Francisco; Moyano, Jose Carlos; Sanchez-Hernandez, Miguel Vicente; Sagredo-Meneses, Víctor; Borras, Rafael; Bastida, Jose María; Hernández-Pérez, Guillermo; Chamorro, Antonio Javier; Marcos, Miguel; Martin-Oterino, Jose Angel.
São Paulo med. j ; 140(1): 123-133, Jan.-Feb. 2022. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1357464

Documentos relacionados

  1. Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study.
  2. Risk Benefit Analysis in Reference to use of LMWH in COVID-19.
  3. Prophylaxis of Venous Thromboembolism in Children: A Systematic Review.
  4. Early treatment with low-molecular-weight heparin reduces mortality rate in SARS-CoV-2 patients.
  5. Clinical Studies with Anticoagulants that Have Changed Clinical Practice.
  6. [Evaluation of anticoagulant effect and predicted dose of low molecular weight heparin in hemodialysis by anti-Ⅹa factor activity].
  7. Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19.
  8. Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration.
  9. Non-severe COVID-19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis.
  10. Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses.